Dexamethasone ophthalmic - InSite Vision

Drug Profile

Dexamethasone ophthalmic - InSite Vision

Alternative Names: Dexamethasone ophthalmic; DexaSite; ISV-305

Latest Information Update: 17 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InSite Vision
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Blepharitis; Ocular inflammation; Ocular pain

Most Recent Events

  • 30 Mar 2018 InSite Vision initiates enrolment in a phase III trial for Blepharitis in USA (NCT01543490)
  • 30 Jan 2018 InSite Vision initiates enrolment in a phase III trial for Ocular Inflammation and Ocular pain (In adolescents, In adults, In the elderly) in USA (Ophthalmic) (NCT03192137)
  • 01 Jan 2018 Phase-III clinical trials in Ocular pain and Ocular inflammation (In adolescents, In adults, In the elderly) in USA (Ophthalmic) (NCT03192150)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top